Analysts expect Spero Therapeutics Inc (NASDAQ:SPRO) to announce earnings per share of ($0.57) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Spero Therapeutics’ earnings. The highest EPS estimate is $0.19 and the lowest is ($0.87). Spero Therapeutics posted earnings per share of ($0.69) in the same quarter last year, which would suggest a positive year-over-year growth rate of 17.4%. The business is expected to issue its next quarterly earnings report on Thursday, August 8th.

On average, analysts expect that Spero Therapeutics will report full-year earnings of ($3.06) per share for the current year, with EPS estimates ranging from ($3.65) to ($2.12). For the next year, analysts forecast that the business will post earnings of ($3.53) per share, with EPS estimates ranging from ($4.11) to ($3.21). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPRO) last announced its earnings results on Thursday, May 9th. The company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.49. The company had revenue of $7.72 million during the quarter, compared to the consensus estimate of $1.25 million. Spero Therapeutics had a negative net margin of 342.70% and a negative return on equity of 34.34%.

SPRO has been the subject of a number of research analyst reports. TheStreet cut shares of Spero Therapeutics from a “c-” rating to a “d” rating in a report on Wednesday, May 8th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $27.00 price target on shares of Spero Therapeutics in a report on Thursday, May 9th. Zacks Investment Research cut shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, March 20th. Finally, Oppenheimer set a $30.00 price target on shares of Spero Therapeutics and gave the stock a “buy” rating in a report on Tuesday, February 26th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $20.25.

Several hedge funds and other institutional investors have recently bought and sold shares of SPRO. Marshall Wace LLP purchased a new position in shares of Spero Therapeutics in the first quarter worth $39,000. Rhumbline Advisers purchased a new position in shares of Spero Therapeutics during the fourth quarter worth $62,000. PNC Financial Services Group Inc. raised its holdings in shares of Spero Therapeutics by 58.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 15,800 shares of the company’s stock worth $98,000 after purchasing an additional 5,800 shares during the last quarter. IHT Wealth Management LLC purchased a new position in shares of Spero Therapeutics during the fourth quarter worth $115,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Spero Therapeutics during the third quarter worth $126,000. 46.70% of the stock is owned by institutional investors and hedge funds.

NASDAQ SPRO opened at $10.38 on Friday. Spero Therapeutics has a 12-month low of $5.52 and a 12-month high of $18.23. The company has a quick ratio of 17.48, a current ratio of 17.48 and a debt-to-equity ratio of 0.04.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

Further Reading: What is the formula for the cash asset ratio?

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.